244 related articles for article (PubMed ID: 9751627)
1. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
[TBL] [Abstract][Full Text] [Related]
2. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
3. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
Zhang X; Feng J; Ye X; Yao Y; Zhou P; Chen X
Gynecol Oncol; 2006 Dec; 103(3):848-52. PubMed ID: 16806435
[TBL] [Abstract][Full Text] [Related]
4. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
Altenschmidt U; Klundt E; Groner B
J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
[TBL] [Abstract][Full Text] [Related]
7. [Anti-tumor effect of lentivirus-mediated MUCI antibody-targeted gene therapy with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice].
Kong B; Wang W; Liu C; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Jiang S
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(17):1207-10. PubMed ID: 12475412
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
[TBL] [Abstract][Full Text] [Related]
10. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
Garrido MA; Valdayo MJ; Winkler DF; Titus JA; Hecht TT; Perez P; Segal DM; Wunderlich JR
Cancer Res; 1990 Jul; 50(14):4227-32. PubMed ID: 2142014
[TBL] [Abstract][Full Text] [Related]
11. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
Cho BK; Roy EJ; Patrick TA; Kranz DM
Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
[TBL] [Abstract][Full Text] [Related]
12. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein.
Coney LR; Tomassetti A; Carayannopoulos L; Frasca V; Kamen BA; Colnaghi MI; Zurawski VR
Cancer Res; 1991 Nov; 51(22):6125-32. PubMed ID: 1840502
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
14. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Rohrbach F; Gerstmayer B; Biburger M; Wels W
Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
[TBL] [Abstract][Full Text] [Related]
15. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice.
Zheng XX; Steele AW; Hancock WW; Kawamoto K; Li XC; Nickerson PW; Li Y; Tian Y; Strom TB
J Immunol; 1999 Oct; 163(7):4041-8. PubMed ID: 10491008
[TBL] [Abstract][Full Text] [Related]
16. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
[TBL] [Abstract][Full Text] [Related]
17. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
19. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
Peng LS; Penichet ML; Morrison SL
J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
[TBL] [Abstract][Full Text] [Related]
20. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
